Endothelial dysfunction in diabetic nephropathy

Advances in Pathogenesis of Diabetic Nephropathy

Volumn , Issue , 2011, Pages 239-271

  Takahashi, Takamune ^a   Harris, Raymond C ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84892014691     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (234)

1. Santilli F, Cipollone F, Mezzetti A, Chiarelli F. The role of nitric oxide in the development of diabetic angiopathy. HormMetab. Res. 2004;36(5): 319-35.
2. Prabhakar SS. Role of nitric oxide in diabetic nephropathy. SeminNephrol. 2004;24(4): 333-44.
3. Balakumar P, Chakkarwar VA, Krishan P, Singh M. Vascular endothelial dysfunction: a tug of war in diabetic nephropathy? Biomed. Pharmacother. 2009 Mar;63(3): 171-9.
4. Albrecht EW, Stegeman CA, Heeringa P, Henning RH, van Goor H. Protective role of endothelial nitric oxide synthase. J.Pathol. 2003;199(1): 8-17.
5. Calles-Escandon J, Cipolla M. Diabetes and endothelial dysfunction: a clinical perspective. Endocr. Rev. 2001 Feb;22(1): 36-52.
6. Forstermann U. Endothelial NO synthase as a source of NO and superoxide. Eur.J.Clin.Pharmacol. 2006;62 Suppl. 13:5-12.
7. Hamilton SJ, Chew GT, Watts GF. Therapeutic regulation of endothelial dysfunction in type 2 diabetes mellitus. Diab. Vasc. Dis. Res. 2007 Jun;4(2): 89-102.
8. Astrup AS, Tarnow L, Pietraszek L, Schalkwijk CG, Stehouwer CD, Parving HH, et al. Markers of endothelial dysfunction and inflammation in type 1 diabetic patients with or without diabetic nephropathy followed for 10 years: association with mortality and decline of glomerular filtration rate. Diabetes Care 2008 Jun;31(6): 1170-6.
9. Stehouwer CD, Gall MA, Twisk JW, Knudsen E, Emeis JJ, Parving HH. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes 2002 Apr;51(4): 1157-65.
10. Schalkwijk CG, Poland DC, van Dijk W, Kok A, Emeis JJ, Drager AM, et al. Plasma concentration of C-reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation. Diabetologia 1999 Mar;42(3): 351-7.
11. Pieper GM. Review of alterations in endothelial nitric oxide production in diabetes: protective role of arginine on endothelial dysfunction. Hypertension1998;31(5):1047-60.
12. Nacci C, Tarquinio M, Montagnani M. Molecular and clinical aspects of endothelial dysfunction in diabetes. Intern. Emerg. Med. 2009 Apr;4(2): 107-16.
13. Rask-Madsen C, King GL. Mechanisms of Disease: endothelial dysfunction in insulin resistance and diabetes. Nat. Clin. Pract. Endocrinol. Metab. 2007 Jan;3(1): 46-56.
14. Li H, Wallerath T, Forstermann U. Physiological mechanisms regulating the expression of endothelial-type NO synthase. NitricOxide2002;7(2):132-47.
15. Dudzinski DM, Igarashi J, Greif D, Michel T.The regulation and pharmacology of endothelial nitric oxide synthase. Annu.Rev.Pharmacol.Toxicol. 2006;46:235-76.
16. Forstermann U, Munzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation 2006 ;Apr113(13): 1708-14.
17. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature2001;414(6865):813-20.
18. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes2005;54(6):1615-25.
19. Zou MH, Cohen R, Ullrich V. Peroxynitrite and vascular endothelial dysfunction in diabetes mellitus. Endothelium2004;11(2):89-97.
20. Moens AL, Kass DA. Tetrahydrobiopterin and cardiovascular disease. Arterioscler Thromb. Vasc. Biol. 2006 Nov;26(11): 2439-44.
21. Sasaki N, Yamashita T, Takaya T, Shinohara M, Shiraki R, Takeda M, et al. Augmentation of vascular remodeling by uncoupled endothelial nitric oxide synthase in a mouse model of diabetes mellitus. Arterioscler. Thromb. Vasc. Biol. 2008 Jun;28(6): 1068-76.
22. Cai S, Khoo J, Channon KM. Augmented BH4 by gene transfer restores nitric oxide synthase function in hyperglycemic human endothelial cells. Cardiovasc. Res. 2005;65(4): 823-31.
23. Cai S, Khoo J, Mussa S, Alp NJ, Channon KM. Endothelial nitric oxide synthase dysfunction in diabetic mice: importance of tetrahydrobiopterin in eNOS dimerisation. Diabetologia2005;48(9):1933-40.
24. Bauersachs J, Schafer A. Tetrahydrobiopterin and eNOS dimer/monomer ratio--a clue to eNOS uncoupling in diabetes? Cardiovasc. Res. 2005;65(4): 768-9.
25. Goumas G, Tentolouris C, Tousoulis D, Stefanadis C, Toutouzas P. Therapeutic modification of the L-arginine-eNOS pathway in cardiovascular diseases. Atherosclerosis 2001 Feb;154(2): 255-67.
26. Pieper GM, Dondlinger LA. Plasma and vascular tissue arginine are decreased in diabetes: acute arginine supplementation restores endothelium-dependent relaxation by augmenting cGMP production. J Pharmacol Exp Ther 1997 Nov;283(2): 684-91.
27. Bank N, Aynedjian HS. Role of EDRF (nitric oxide) in diabetic renal hyperfiltration. Kidney Int1993;43(6):1306-12.
28. Craven PA, Studer RK, DeRubertis FR. Impaired nitric oxide-dependent cyclic guanosine monophosphate generation in glomeruli from diabetic rats. Evidence for protein kinase C-mediated suppression of the cholinergic response. J. ClinInvest. 1994;93(1): 311-20.
29. Durante W, Johnson FK, Johnson RA. Arginase: a critical regulator of nitric oxide synthesis and vascular function. Clin Exp Pharmacol Physiol 2007 Sep;34(9): 906-11.
30. Bivalacqua TJ, Hellstrom WJ, Kadowitz PJ, Champion HC. Increased expression of arginase II in human diabetic corpus cavernosum: in diabetic-associated erectile dysfunction. Biochem. Biophys. Res. Commun. 2001 May;283(4): 923-7.
31. Kampfer H, Pfeilschifter J, Frank S. Expression and activity of arginase isoenzymes during normal and diabetes-impaired skin repair. J. Invest. Dermatol. 2003 Dec;121(6): 1544-51.
32. Romero MJ, Platt DH, Tawfik HE, Labazi M, El-Remessy AB, Bartoli M, et al. Diabetes-induced coronary vascular dysfunction involves increased arginase activity. Circ. Res. 2008 Jan;102(1): 95-102.
33. Palm F, Onozato ML, Luo Z, Wilcox CS. Dimethylarginine dimethylaminohydrolase (DDAH): expression, regulation, and function in the cardiovascular and renal systems. Am. J. Physiol. Heart. Circ. Physiol. 2007 Dec;293(6):H3227-45.
34. Yamagishi S, Ueda S, Nakamura K, Matsui T, Okuda S. Role of asymmetric dimethylarginine (ADMA) in diabetic vascular complications. Curr. Pharm. Des2008;14(25):2613-8.
35. Krzyzanowska K, Mittermayer F, Wolzt M, Schernthaner G. ADMA, cardiovascular disease and diabetes. Diabetes Res. Clin. Pract. 2008 Dec 15;82 Suppl 2:S122-6.
36. Tarnow L, Hovind P, Teerlink T, Stehouwer CD, Parving HH. Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes. Diabetes Care 2004 Mar;27(3): 765-9.
37. Krzyzanowska K, Mittermayer F, Krugluger W, Schnack C, Hofer M, Wolzt M, et al. Asymmetric dimethylarginine is associated with macrovascular disease and total homocysteine in patients with type 2 diabetes. Atherosclerosis 2006 Nov;189(1): 236-40.
38. Krzyzanowska K, Mittermayer F, Shnawa N, Hofer M, Schnabler J, Etmuller Y, et al. Asymmetrical dimethylarginine is related to renal function, chronic inflammation and macroangiopathy in patients with Type 2 diabetes and albuminuria. Diabet. Med. 2007 Jan;24(1): 81-6.
39. Satchell SC, Tooke JE. What is the mechanism of microalbuminuria in diabetes: a role for the glomerular endothelium? Diabetologia 2008 May;51(5):714-25.
40. Stehouwer CD, Fischer HR, van Kuijk AW, Polak BC, Donker AJ. Endothelial dysfunction precedes development of microalbuminuria in IDDM. Diabetes 1995 May;44(5): 561-4.
41. Hiragushi K, Sugimoto H, Shikata K, Yamashita T, Miyatake N, Shikata Y, et al. Nitric oxide system is involved in glomerular hyperfiltration in Japanese normo-and micro-albuminuric patients with type 2 diabetes. Diabetes Res. Clin. Pract 2001 Sep;53(3): 149-59.
42. Delles C, Klingbeil AU, Schneider MP, Handrock R, Schaufele T, Schmieder RE. The role of nitric oxide in the regulation of glomerular haemodynamics in humans. Nephrol Dial. Transplant. 2004 Jun;19(6): 1392-7.
43. Chiarelli F, Cipollone F, Romano F, Tumini S, Costantini F, di Ricco L, et al. Increased circulating nitric oxide in young patients with type 1 diabetes and persistent microalbuminuria: relation to glomerular hyperfiltration. Diabetes 2000 Jul;49(7): 1258-63.
44. Maejima K, Nakano S, Himeno M, Tsuda S, Makiishi H, Ito T, et al. Increased basal levels of plasma nitric oxide in Type 2 diabetic subjects. Relationship to microvascular complications. J. Diabetes Complications 2001 May-Jun;15(3): 135-43.
45. Earle KA, Mehrotra S, Dalton RN, Denver E, Swaminathan R. Defective nitric oxide production and functional renal reserve in patients with type 2 diabetes who have microalbuminuria of African and Asian compared with white origin. J. Am. Soc. Nephrol. 2001 Oct;12(10): 2125-30.
46. Hohenstein B, Hugo CP, Hausknecht B, Boehmer KP, Riess RH, Schmieder RE. Analysis of NO-synthase expression and clinical risk factors in human diabetic nephropathy. Nephrol. Dial. Transplant. 2008 Apr;23(4): 1346-54.
47. Ng DP, Krolewski AS. Molecular genetic approaches for studying the etiology of diabetic nephropathy. Curr. Mol. Med. 2005 Aug;5(5): 509-25.
48. Zanchi A, Moczulski DK, Hanna LS, Wantman M, Warram JH, Krolewski AS. Risk of advanced diabetic nephropathy in type 1 diabetes is associated with endothelial nitric oxide synthase gene polymorphism. Kidney Int. 2000;57(2): 405-13.
49. Shin Shin Y, Baek SH, Chang KY, Park CW, Yang CW, Jin DC, et al. Relations between eNOS Glu298Asp polymorphism and progression of diabetic nephropathy. Diabetes Res. Clin. Pract. 2004 Sep;65(3): 257-65.
50. Ahluwalia TS, Ahuja M, Rai TS, Kohli HS, Sud K, Bhansali A, et al. Endothelial nitric oxide synthase gene haplotypes and diabetic nephropathy among Asian Indians. Mol. Cell Biochem. 2008 Jul;314(1-2):9-17.
51. Liu Y, Burdon KP, Langefeld CD, Beck SR, Wagenknecht LE, Rich SS, et al. T-786C polymorphism of the endothelial nitric oxide synthase gene is associated with albuminuria in the diabetes heart study. J.Am.Soc.Nephrol. 2005;16(4): 1085-90.
52. Noiri E, Satoh H, Taguchi J, Brodsky SV, Nakao A, Ogawa Y, et al. Association of eNOS Glu298Asp polymorphism with end-stage renal disease. Hypertension2002;40(4):535-40.
53. Nagase S, Suzuki H, Wang Y, Kikuchi S, Hirayama A, Ueda A, et al. Association of ecNOS gene polymorphisms with end stage renal diseases. Mol. Cell Biochem. 2003 Feb;244(1-2):113-8.
54. Suzuki H, Nagase S, Kikuchi S, Wang Y, Koyama A. Association of a missense Glu298Asp mutation of the endothelial nitric oxide synthase gene with end stage renal disease. Clin. Chem. 2000 Nov;46(11): 1858-60.
55. Asakimori Y, Yorioka N, Taniguchi Y, Ito T, Ogata S, Kyuden Y, et al. T(-786)-->C polymorphism of the endothelial nitric oxide synthase gene influences the progression of renal disease. Nephron 2002 Aug;91(4): 747-51.
56. Wang XL, Mahaney MC, Sim AS, Wang J, Blangero J, Almasy L, et al. Genetic contribution of the endothelial constitutive nitric oxide synthase gene to plasma nitric oxide levels. Arterioscler. Thromb. Vasc. Biol. 1997 Nov;17(11): 3147-53.
57. Asakimori Y, Yorioka N, Yamamoto I, Okumoto S, Doi S, Hirai T, et al. Endothelial nitric oxide synthase intron 4 polymorphism influences the progression of renal disease. Nephron. 2001 Oct;89(2): 219-23.
58. Neugebauer S, Baba T, Watanabe T. Association of the nitric oxide synthase gene polymorphism with an increased risk for progression to diabetic nephropathy in type 2 diabetes. Diabetes2000;49(3):500-3.
59. Ksiazek P, Wojewoda P, Muc K, Buraczynska M. Endothelial nitric oxide synthase gene intron 4 polymorphism in type 2 diabetes mellitus. MolDiagn2003;7(2):119-23.
60. Fujita H, Narita T, Meguro H, Ishii T, Hanyu O, Suzuki K, et al. Lack of association between an ecNOS gene polymorphism and diabetic nephropathy in type 2 diabetic patients with proliferative diabetic retinopathy. Horm. Metab. Res. 2000 Feb;32(2): 80-3.
61. Noiri E, Satoh H, Taguchi J, Brodsky SV, Nakao A, Ogawa Y, et al. Association of eNOS Glu298Asp polymorphism with end-stage renal disease. Hypertension. 2002 Oct;40(4): 535-40.
62. Lin S, Qu H, Qiu M. Allele A in intron 4 of ecNOS gene will not increase the risk of diabetic nephropathy in type 2 diabetes of Chinese population. Nephron 2002 Aug;91(4): 768.
63. Rippin JD, Patel A, Belyaev ND, Gill GV, Barnett AH, Bain SC. Nitric oxide synthase gene polymorphisms and diabetic nephropathy. Diabetologia 2003 Mar;46(3): 426-8.
64. Degen B, Schmidt S, Ritz E. A polymorphism in the gene for the endothelial nitric oxide synthase and diabetic nephropathy. Nephrol. Dial Transplant. 2001 Jan;16(1): 185.
65. Freedman BI, Yu H, Anderson PJ, Roh BH, Rich SS, Bowden DW. Genetic analysis of nitric oxide and endothelin in end-stage renal disease. Nephrol. Dial. Transplant. 2000 Nov;15(11): 1794-800.
66. Shimizu T, Onuma T, Kawamori R, Makita Y, Tomino Y. Endothelial nitric oxide synthase gene and the development of diabetic nephropathy. Diabetes Res. Clin. Pract. 2002 Dec;58(3): 179-85.
67. Komers R, Anderson S.Paradoxes of nitric oxide in the diabetic kidney. Am.J.Physiol. Renal. Physiol. 2003;284(6): F1121-F37.
68. Kone BC. Localization and regulation of nitric oxide synthase isoforms in the kidney. Semin. Nephrol. 1999 May;19(3): 230-41.
69. Bachmann S, Bosse HM, Mundel P. Topography of nitric oxide synthesis by localizing constitutive NO synthases in mammalian kidney. Am. .J Physiol. 1995 May;268(5 Pt 2):F885-98.
70. Han KH, Lim JM, Kim WY, Kim H, Madsen KM, Kim J.Expression of endothelial nitric oxide synthase in developing rat kidney. Am.J.Physiol. Renal Physiol. 2005;288(4): F694-F702.
71. Furusu A, Miyazaki M, Abe K, Tsukasaki S, Shioshita K, Sasaki O, et al. Expression of endothelial and inducible nitric oxide synthase in human glomerulonephritis. Kidney Int. 1998;53(6): 1760-8.
72. Choi KC, Kim NH, An MR, Kang DG, Kim SW, Lee J. Alterations of intrarenal renin-angiotensin and nitric oxide systems in streptozotocin-induced diabetic rats. Kidney Int. Suppl 1997 Sep;60:S23-7.
73. Sugimoto H, Shikata K, Matsuda M, Kushiro M, Hayashi Y, Hiragushi K, et al.Increased expression of endothelial cell nitric oxide synthase (ecNOS) in afferent and glomerular endothelial cells is involved in glomerular hyperfiltration of diabetic nephropathy. Diabetologia 1998;41(12): 1426-34.
74. Shin SJ, Lai FJ, Wen JD, Hsiao PJ, Hsieh MC, Tzeng TF, et al.Neuronal and endothelial nitric oxide synthase expression in outer medulla of streptozotocin-induced diabetic rat kidney. Diabetologia 2000;43(5): 649-59.
75. Veelken R, Hilgers KF, Hartner A, Haas A, Bohmer KP, Sterzel RB. Nitric oxide synthase isoforms and glomerular hyperfiltration in early diabetic nephropathy. J. Am. Soc. Nephrol. 2000 Jan;11(1): 71-9.
76. Vriese AS, Tilton RG, Elger M, Stephan CC, Kriz W, Lameire NH. Antibodies against Vascular Endothelial Growth Factor Improve Early Renal Dysfunction in Experimental Diabetes. J.Am.Soc.Nephrol. 2001 May;12(5):993-1000.
77. De Vriese AS, Stoenoiu MS, Elger M, Devuyst O, Vanholder R, Kriz W, et al. Diabetes-induced microvascular dysfunction in the hydronephrotic kidney: role of nitric oxide. Kidney Int. 2001 Jul;60(1): 202-10.
78. Onozato ML, Tojo A, Goto A, Fujita T, Wilcox CS. Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB. Kidney Int. 2002 Jan;61(1): 186-94.
79. Keynan S, Hirshberg B, Levin-Iaina N, Wexler ID, Dahan R, Reinhartz E, et al. Renal nitric oxide production during the early phase of experimental diabetes mellitus. Kidney Int. 2000;58(2): 740-7.
80. Ishii N, Patel KP, Lane PH, Taylor T, Bian K, Murad F, et al. Nitric oxide synthesis and oxidative stress in the renal cortex of rats with diabetes mellitus. J. Am. Soc. Nephrol. 2001 Aug;12(8): 1630-9.
81. Schwartz D, Schwartz IF, Blantz RC. An analysis of renal nitric oxide contribution to hyperfiltration in diabetic rats. J. Lab. Clin. Med. 2001 Feb;137(2): 107-14.
82. Kasai N, Sugimoto K, Horiba N, Suda T. Effect of D-glucose on nitric oxide release from glomerular endothelial cells. Diabetes Metab. Res. Rev. 2001 May-Jun;17(3): 217-22.
83. Hoshiyama M, Li B, Yao J, Harada T, Morioka T, Oite T.Effect of high glucose on nitric oxide production and endothelial nitric oxide synthase protein expression in human glomerular endothelial cells. Nephron Exp.Nephrol. 2003;95(2): e62-e8.
84. Cooper ME, Vranes D, Youssef S, Stacker SA, Cox AJ, Rizkalla B, et al.Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes 1999;48(11): 2229-39.
85. Wang Y, Nagase S, Koyama A. Stimulatory effect of IGF-I and VEGF on eNOS message, protein expression, eNOS phosphorylation and nitric oxide production in rat glomeruli, and the involvement of PI3-K signaling pathway. Nitric.Oxide. 2004;10(1): 25-35.
86. Tolins JP, Shultz PJ, Raij L, Brown DM, Mauer SM. Abnormal renal hemodynamic response to reduced renal perfusion pressure in diabetic rats: role of NO. Am. J. Physiol. 1993 Dec;265(6 Pt 2):F886-95.
87. Komers R, Allen TJ, Cooper ME. Role of endothelium-derived nitric oxide in the pathogenesis of the renal hemodynamic changes of experimental diabetes. Diabetes 1994 Oct;43(10): 1190-7.
88. Mattar AL, Fujihara CK, Ribeiro MO, de Nucci G, Zatz R.Renal effects of acute and chronic nitric oxide inhibition in experimental diabetes. Nephron 1996;74(1): 136-43.
89. Omer S, Shan J, Varma DR, Mulay S. Augmentation of diabetes-associated renal hyperfiltration and nitric oxide production by pregnancy in rats. J. Endocrinol. 1999 Apr;161(1): 15-23.
90. Wang YX, Brooks DP, Edwards RM. Attenuated glomerular cGMP production and renal vasodilation in streptozotocin-induced diabetic rats. Am. J. Physiol. 1993 May;264(5 Pt 2):R952-6.
91. Satoh M, Fujimoto S, Haruna Y, Arakawa S, Horike H, Komai N, et al.NAD(P)H oxidase and uncoupled nitric oxide synthase are major sources of glomerular superoxide in rats with experimental diabetic nephropathy. Am.J.Physiol. Renal. Physiol. 2005;288(6): F1144-F52.
92. Chu S, Bohlen HG.High concentration of glucose inhibits glomerular endothelial eNOS through a PKC mechanism. Am.J.Physiol. Renal. Physiol. 2004;287(3): F384-92.
93. Wilcox CS, Welch WJ, Murad F, Gross SS, Taylor G, Levi R, et al. Nitric oxide synthase in macula densa regulates glomerular capillary pressure. Proc. Natl. Acad. Sci. U S A 1992 Dec;89(24): 11993-7.
94. Thorup C, Erik A, Persson G. Macula densa derived nitric oxide in regulation of glomerular capillary pressure. Kidney Int. 1996 Feb;49(2): 430-6.
95. Ichihara A, Inscho EW, Imig JD, Navar LG. Neuronal nitric oxide synthase modulates rat renal microvascular function. Am. J. Physiol. 1998 Mar;274(3 Pt 2):F516-24.
96. Komers R, Oyama TT, Chapman JG, Allison KM, Anderson S. Effects of systemic inhibition of neuronal nitric oxide synthase in diabetic rats. Hypertension 2000 Feb;35(2): 655-61.
97. Komers R, Lindsley JN, Oyama TT, Allison KM, Anderson S. Role of neuronal nitric oxide synthase (NOS1) in the pathogenesis of renal hemodynamic changes in diabetes. Am. J. Physiol. Renal. Physiol. 2000 Sep;279(3): F573-83.
98. Ito A, Uriu K, Inada Y, Qie YL, Takagi I, Ikeda M, et al. Inhibition of neuronal nitric oxide synthase ameliorates renal hyperfiltration in streptozotocin-induced diabetic rat. J. Lab. Clin. Med. 2001 Sep;138(3): 177-85.
99. Levine DZ, Iacovitti M, Robertson SJ, Mokhtar GA.Modulation of single-nephron GFR in the db/db mouse model of type 2 diabetes mellitus. Am.J.Physiol. RegulIntegr.Comp. Physiol. 2006;290(4): R975-R81.
100. Pieper GM.Enhanced, unaltered and impaired nitric oxide-mediated endothelium-dependent relaxation in experimental diabetes mellitus: importance of disease duration. Diabetologia 1999;42(2): 204-13.
101. Erdely A, Freshour G, Maddox DA, Olson JL, Samsell L, Baylis C.Renal disease in rats with type 2 diabetes is associated with decreased renal nitric oxide production. Diabetologia 2004;47(10): 1672-6.
102. Khamaisi M, Keynan S, Bursztyn M, Dahan R, Reinhartz E, Ovadia H, et al. Role of Renal Nitric Oxide Synthase in Diabetic Kidney Disease during the Chronic Phase of Diabetes. Nephron Physiol. 2005;102(3-4):72-80.
103. Yuzawa Y, Niki I, Kosugi T, Maruyama S, Yoshida F, Takeda M, et al. Overexpression of calmodulin in pancreatic beta cells induces diabetic nephropathy. J. Am. Soc. Nephrol. 2008 Sep;19(9): 1701-11.
104. Craven PA, DeRubertis FR, Melhem M. Nitric oxide in diabetic nephropathy. Kidney Int. Suppl 1997 Sep;60:S46-53.
105. Soulis T, Cooper ME, Sastra S, Thallas V, Panagiotopoulos S, Bjerrum OJ, et al. Relative contributions of advanced glycation and nitric oxide synthase inhibition to aminoguanidine-mediated renoprotection in diabetic rats. Diabetologia 1997 Oct;40(10): 1141-51.
106. Kamijo H, Higuchi M, Hora K.Chronic inhibition of nitric oxide production aggravates diabetic nephropathy in Otsuka Long-Evans Tokushima Fatty rats. Nephron. Physiol. 2006;104(1): p12-22.
107. Huang PL. Mouse models of nitric oxide synthase deficiency. J.Am.Soc.Nephrol. 2000;11 Suppl. 16:S120-3.
108. Zhao HJ, Wang S, Cheng H, Zhang MZ, Takahashi T, Fogo AB, et al. Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in diabetic mice. J.Am.Soc.Nephrol. 2006;17(10): 2664-9.
109. Mohan S, Reddick RL, Musi N, Horn DA, Yan B, Prihoda TJ, et al. Diabetic eNOS knockout mice develop distinct macro-and microvascular complications. Lab. Invest. 2008 May;88(5): 515-28.
110. Nakagawa T, Sato W, Glushakova O, Heinig M, Clarke T, Campbell-Thompson M, et al. Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy. J.Am.Soc.Nephrol. 2007;18(2): 539-50.
111. Kanetsuna Y, Takahashi K, Nagata M, Gannon MA, Breyer MD, Harris RC, et al. Deficiency of endothelial nitric-oxide synthase confers susceptibility to diabetic nephropathy in nephropathy-resistant inbred mice. Am.J.Pathol. 2007;170(5): 1473-84.
112. Kosugi T, Heinig M, Nakayama T, Connor T, Yuzawa Y, Li Q, et al. Lowering blood pressure blocks mesangiolysis and mesangial nodules, but not tubulointerstitial injury, in diabetic eNOS knockout mice. Am. J. Pathol. 2009 Apr;174(4): 1221-9.
113. Suzuki H, Kimura K, Shirai H, Eguchi K, Higuchi S, Hinoki A, et al. Endothelial nitric oxide synthase inhibits G12/13 and rho-kinase activated by the angiotensin II type-1 receptor: implication in vascular migration. Arterioscler. Thromb. Vasc. Biol. 2009 Feb;29(2): 217-24.
114. Johnson RJ, Herrera-Acosta J, Schreiner GF, Rodriguez-Iturbe B. Subtle acquired renal injury as a mechanism of salt-sensitive hypertension. N. Engl. J. Med. 2002 Mar;346(12): 913-23.
115. Quiroz Y, Pons H, Gordon KL, Rincon J, Chavez M, Parra G, et al. Mycophenolate mofetil prevents salt-sensitive hypertension resulting from nitric oxide synthesis inhibition. Am. J. Physiol. Renal. Physiol. 2001 Jul;281(1): F38-47.
116. Edwards RM, Trizna W. Modulation of glomerular arteriolar tone by nitric oxide synthase inhibitors. J. Am. Soc. Nephrol. 1993 Nov;4(5): 1127-32.
117. Patzak A, Kleinmann F, Lai EY, Kupsch E, Skelweit A, Mrowka R. Nitric oxide counteracts angiotensin II induced contraction in efferent arterioles in mice. Acta Physiol. Scand. 2004 Aug;181(4): 439-44.
118. Ho FM, Lin WW, Chen BC, Chao CM, Yang CR, Lin LY, et al. High glucose-induced apoptosis in human vascular endothelial cells is mediated through NF-kappaB and c-Jun NH2-terminal kinase pathway and prevented by PI3K/Akt/eNOS pathway. Cell Signal. 2006;18(3): 391-9.
119. Peng HB, Libby P, Liao JK. Induction and stabilization of I kappa B alpha by nitric oxide mediates inhibition of NF-kappa B. J.Biol.Chem. 1995;270(23): 14214-9.
120. De Caterina R, Libby P, Peng HB, Thannickal VJ, Rajavashisth TB, Gimbrone MA, Jr., et al. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J.ClinInvest. 1995;96(1): 60-8.
121. Peng HB, Rajavashisth TB, Libby P, Liao JK. Nitric oxide inhibits macrophage-colony stimulating factor gene transcription in vascular endothelial cells. J.Biol.Chem. 1995;270(28): 17050-5.
122. Liu XM, Peyton KJ, Ensenat D, Wang H, Hannink M, Alam J, et al. Nitric oxide stimulates heme oxygenase-1 gene transcription via the Nrf2/ARE complex to promote vascular smooth muscle cell survival. Cardiovasc. Res. 2007 Jul;75(2): 381-9.
123. Hayashi T, Matsui-Hirai H, Miyazaki-Akita A, Fukatsu A, Funami J, Ding QF, et al. Endothelial cellular senescence is inhibited by nitric oxide: implications in atherosclerosis associated with menopause and diabetes. Proc. Natl. Acad. Sci. U S A. 2006 Nov;103(45): 17018-23.
124. Sanders PW. Vascular Consequences of Dietary Salt Intake. Am. J. Physiol. Renal. Physiol. 2009 Aug;297(2): F237-43.
125. Nakagawa T, Sato W, Sautin YY, Glushakova O, Croker B, Atkinson MA, et al. Uncoupling of vascular endothelial growth factor with nitric oxide as a mechanism for diabetic vasculopathy. J .Am. Soc. Nephrol. 2006 Mar;17(3): 736-45.
126. Sato W, Kosugi T, Zhang L, Roncal CA, Heinig M, Campbell-Thompson M, et al. The pivotal role of VEGF on glomerular macrophage infiltration in advanced diabetic nephropathy. Lab. Invest. 2008 Sep;88(9): 949-61.
127. Haase VH. Hypoxia-inducible factors in the kidney. Am. J. Physiol. Renal. Physiol. 2006 Aug;291(2): F271-81.
128. London NR, Whitehead KJ, Li DY. Endogenous endothelial cell signaling systems maintain vascular stability. Angiogenesis 2009;12(2): 149-58.
129. Jeansson M, Haraldsson B. Glomerular size and charge selectivity in the mouse after exposure to glucosaminoglycan-degrading enzymes. J. Am. Soc. Nephrol. 2003; 14(7):1756-65.
130. Jeansson M, Haraldsson B.Morphological and functional evidence for an important role of the endothelial cell glycocalyx in the glomerular barrier. Am J Physiol Renal Physiol. 2006;290(1): F111-6.
131. Arcos MI, Fujihara CK, Sesso A, Almeida Prado EB, Almeida Prado MJ, De Nucci G, et al.Mechanisms of albuminuria in the chronic nitric oxide inhibition model. Am. J.Physiol. Renal. Physiol. 2000;279(6): F1060-6.
132. Maxhimer JB, Somenek M, Rao G, Pesce CE, Baldwin D, Jr., Gattuso P, et al. Heparanase-1 gene expression and regulation by high glucose in renal epithelial cells: a potential role in the pathogenesis of proteinuria in diabetic patients. Diabetes 2005 Jul;54(7): 2172-8.
133. Lewis EJ, Xu X. Abnormal glomerular permeability characteristics in diabetic nephropathy: implications for the therapeutic use of low-molecular weight heparin. Diabetes Care 2008 Feb;31 Suppl 2:S202-7.
134. Sharma M, McCarthy ET, Savin VJ, Lianos EA. Nitric oxide preserves the glomerular protein permeability barrier by antagonizing superoxide. Kidney Int. 2005 Dec;68(6): 2735-44.
135. Sharma M, Zou Z, Miura H, Papapetropoulos A, McCarthy ET, Sharma R, et al. ADMA Injures Glomerular Filtration Barrier: Role of Nitric Oxide and Superoxide. Am J. Physiol. Renal. Physiol. 2009 Jun;296(6): F1386-95.
136. Fulton DJ. Mechanisms of vascular insulin resistance: a substitute Akt? Circ. Res. 2009 May;104(9): 1035-7.
137. Quaschning T, Voss F, Relle K, Kalk P, Vignon-Zellweger N, Pfab T, et al. Lack of endothelial nitric oxide synthase promotes endothelin-induced hypertension: lessons from endothelin-1 transgenic/endothelial nitric oxide synthase knockout mice. J. Am. Soc. Nephrol. 2007 Mar;18(3): 730-40.
138. Baelde HJ, Eikmans M, Lappin DW, Doran PP, Hohenadel D, Brinkkoetter PT, et al. Reduction of VEGF-A and CTGF expression in diabetic nephropathy is associated with podocyte loss. Kidney Int. 2007 Apr;71(7): 637-45.
139. Doublier S, Salvidio G, Lupia E, Ruotsalainen V, Verzola D, Deferrari G, et al. Nephrin expression is reduced in human diabetic nephropathy: evidence for a distinct role for glycated albumin and angiotensin II. Diabetes 2003 Apr;52(4): 1023-30.
140. Toyoda M, Najafian B, Kim Y, Caramori ML, Mauer M. Podocyte detachment and reduced glomerular capillary endothelial fenestration in human type 1 diabetic nephropathy. Diabetes 2007 Aug;56(8): 2155-60.
141. Morita T, Yamamoto T, Churg J. Mesangiolysis: an update. Am.J.Kidney Dis. 1998;31(4): 559-73.
142. Kleinbongard P, Schulz R, Rassaf T, Lauer T, Dejam A, Jax T, et al. Red blood cells express a functional endothelial nitric oxide synthase. Blood 2006 Apr;107(7): 2943-51.
143. Feng Q, Song W, Lu X, Hamilton JA, Lei M, Peng T, et al.Development of heart failure and congenital septal defects in mice lacking endothelial nitric oxide synthase. Circulation 2002;106(7): 873-9.
144. Lee TC, Zhao YD, Courtman DW, Stewart DJ.Abnormal aortic valve development in mice lacking endothelial nitric oxide synthase. Circulation 2000;101(20): 2345-8.
145. Han RN, Babaei S, Robb M, Lee T, Ridsdale R, Ackerley C, et al.Defective lung vascular development and fatal respiratory distress in endothelial NO synthase-deficient mice: a model of alveolar capillary dysplasia? Circ. Res. 2004;94(8): 1115-23.
146. Forbes MS, Thornhill BA, Park MH, Chevalier RL. Lack of endothelial nitric-oxide synthase leads to progressive focal renal injury. Am .J. Pathol. 2007 Jan;170(1): 87-99.
147. Fleming I, Busse R. Molecular mechanisms involved in the regulation of the endothelial nitric oxide synthase. Am J Physiol Regul Integr Comp Physiol 2003 Jan;284(1): R1-12.
148. Govers R, Rabelink TJ. Cellular regulation of endothelial nitric oxide synthase. Am. J. Physiol. Renal Physiol. 2001 Feb;280(2): F193-206.
149. Igarashi J, Michel T. S1P and eNOS regulation. Biochim. Biophys. Acta 2008 Sep;1781(9): 489-95.
150. Imasawa T, Kitamura H, Ohkawa R, Satoh Y, Miyashita A, Yatomi Y. Unbalanced expression of sphingosine 1-phosphate receptors in diabetic nephropathy. Exp. Toxicol. Pathol. 2010 Jan;62(1): 53-60.
151. Duncan ER, Crossey PA, Walker S, Anilkumar N, Poston L, Douglas G, et al. Effect of endothelium-specific insulin resistance on endothelial function in vivo. Diabetes 2008 Dec;57(12): 3307-14.
152. Kearney MT, Duncan ER, Kahn M, Wheatcroft SB. Insulin resistance and endothelial cell dysfunction: studies in mammalian models. Exp. Physiol. 2008 Jan;93(1): 158-63.
153. Giugliano D, Marfella R, Coppola L, Verrazzo G, Acampora R, Giunta R, et al. Vascular effects of acute hyperglycemia in humans are reversed by L-arginine. Evidence for reduced availability of nitric oxide during hyperglycemia. Circulation 1997 Apr;95(7): 1783-90.
154. Brodsky SV, Morrishow AM, Dharia N, Gross SS, Goligorsky MS. Glucose scavenging of nitric oxide. Am.J.Physiol.Renal. Physiol. 2001 Mar;280(3):F480-6;280(3):F480-6.
155. Du XL, Edelstein D, Dimmeler S, Ju Q, Sui C, Brownlee M. Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J.ClinInvest. 2001;108(9): 1341-8.
156. Fleming I, Fisslthaler B, Dimmeler S, Kemp BE, Busse R. Phosphorylation of Thr(495) regulates Ca(2+)/calmodulin-dependent endothelial nitric oxide synthase activity. Circ. Res. 2001 Jun 8;88(11): E68-75.
157. Michell BJ, Chen Z, Tiganis T, Stapleton D, Katsis F, Power DA, et al. Coordinated control of endothelial nitric-oxide synthase phosphorylation by protein kinase C and the cAMP-dependent protein kinase. J. Biol. Chem. 2001 May;276(21): 17625-8.
158. Matsubara M, Titani K, Taniguchi H. Interaction of calmodulin-binding domain peptides of nitric oxide synthase with membrane phospholipids: regulation by protein phosphorylation and Ca(2+)-calmodulin. Biochemistry 1996 Nov;35(46): 14651-8.
159. Naruse K, Rask-Madsen C, Takahara N, Ha SW, Suzuma K, Way KJ, et al. Activation of vascular protein kinase C-beta inhibits Akt-dependent endothelial nitric oxide synthase function in obesity-associated insulin resistance. Diabetes 2006 Mar;55(3): 691-8.
160. Ozcan U, Cao Q, Yilmaz E, Lee AH, Iwakoshi NN, Ozdelen E, et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 2004 Oct;306(5695): 457-61.
161. Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes 1998 Jun;47(6): 859-66.
162. Xu B, Chibber R, Ruggiero D, Kohner E, Ritter J, Ferro A.Impairment of vascular endothelial nitric oxide synthase activity by advanced glycation end products. FASEB J 2003;17(10): 1289-91.
163. Rashid G, Benchetrit S, Fishman D, Bernheim J. Effect of advanced glycation end-products on gene expression and synthesis of TNF-alpha and endothelial nitric oxide synthase by endothelial cells. Kidney Int. 2004;66(3): 1099-106.
164. Bucala R, Tracey KJ, Cerami A.Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J.ClinInvest 1991;87(2): 432-8.
165. Yoshizumi M, Perrella MA, Burnett JC, Jr., Lee ME. Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circ. Res. 1993 Jul;73(1): 205-9.
166. Li G, Barrett EJ, Barrett MO, Cao W, Liu Z. Tumor necrosis factor-alpha induces insulin resistance in endothelial cells via a p38 mitogen-activated protein kinase-dependent pathway. Endocrinology 2007 Jul;148(7): 3356-63.
167. Anderson HD, Rahmutula D, Gardner DG. Tumor necrosis factor-alpha inhibits endothelial nitric-oxide synthase gene promoter activity in bovine aortic endothelial cells. J. Biol. Chem. 2004 Jan;279(2): 963-9.
168. Makino N, Maeda T, Sugano M, Satoh S, Watanabe R, Abe N. High serum TNF-alpha level in Type 2 diabetic patients with microangiopathy is associated with eNOS down-regulation and apoptosis in endothelial cells. J Diabetes Complications 2005 Nov-Dec;19(6): 347-55.
169. Goodwin BL, Pendleton LC, Levy MM, Solomonson LP, Eichler DC. Tumor necrosis factor-alpha reduces argininosuccinate synthase expression and nitric oxide production in aortic endothelial cells. Am. J. Physiol. Heart. Circ. Physiol. 2007 Aug;293(2): H1115-21.
170. Wang XL, Zhang L, Youker K, Zhang MX, Wang J, LeMaire SA, et al. Free fatty acids inhibit insulin signaling-stimulated endothelial nitric oxide synthase activation through upregulating PTEN or inhibiting Akt kinase. Diabetes 2006 Aug;55(8): 2301-10.
171. Kim F, Tysseling KA, Rice J, Pham M, Haji L, Gallis BM, et al. Free fatty acid impairment of nitric oxide production in endothelial cells is mediated by IKKbeta. Arterioscler. Thromb. Vasc. Biol. 2005 May;25(5): 989-94.
172. Cooke JP. Does ADMA cause endothelial dysfunction? Arterioscler. Thromb. Vasc. Biol. 2000 Sep;20(9): 2032-7.
173. Toutouzas K, Riga M, Stefanadi E, Stefanadis C. Asymmetric dimethylarginine (ADMA) and other endogenous nitric oxide synthase (NOS) inhibitors as an important cause of vascular insulin resistance. Horm. Metab. Res. 2008 Sep;40(9): 655-9.
174. Boger RH, Bode-Boger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998 Nov;98(18): 1842-7.
175. Hand MF, Haynes WG, Webb DJ. Hemodialysis and L-arginine, but not D-arginine, correct renal failure-associated endothelial dysfunction. Kidney Int. 1998 Apr;53(4): 1068-77.
176. Onozato ML, Tojo A, Leiper J, Fujita T, Palm F, Wilcox CS. Expression of NG,NG-dimethylarginine dimethylaminohydrolase and protein arginine N-methyltransferase isoforms in diabetic rat kidney: effects of angiotensin II receptor blockers. Diabetes 2008 Jan;57(1): 172-80.
177. Wang D, Gill PS, Chabrashvili T, Onozato ML, Raggio J, Mendonca M, et al. Isoform-specific regulation by N(G),N(G)-dimethylarginine dimethylaminohydrolase of rat serum asymmetric dimethylarginine and vascular endothelium-derived relaxing factor/NO. Circ. Res. 2007 Sep;101(6): 627-35.
178. Leiper J, Nandi M, Torondel B, Murray-Rust J, Malaki M, O'Hara B, et al. Disruption of methylarginine metabolism impairs vascular homeostasis. Nat. Med 2007 Feb;13(2): 198-203.
179. Shibata R, Ueda S, Yamagishi S, Kaida Y, Matsumoto Y, Fukami K, et al. Involvement of asymmetric dimethylarginine (ADMA) in tubulointerstitial ischaemia in the early phase of diabetic nephropathy. Nephrol. Dial. Transplant. 2009 Apr;24(4): 1162-9.
180. Eid HM, Lyberg T, Arnesen H, Seljeflot I. Insulin and adiponectin inhibit the TNFalpha-induced ADMA accumulation in human endothelial cells: the role of DDAH. Atherosclerosis 2007 Oct;194(2): e1-8.
181. Sorrenti V, Mazza F, Campisi A, Vanella L, Li Volti G, Di Giacomo C. High glucose-mediated imbalance of nitric oxide synthase and dimethylarginine dimethylaminohydrolase expression in endothelial cells. Curr. Neurovasc. Res. 2006 Feb;3(1): 49-54.
182. Lu CW, Xiong Y, He P. Dimethylarginine dimethylaminohydrolase-2 overexpression improves impaired nitric oxide synthesis of endothelial cells induced by glycated protein. Nitric Oxide 2007 Feb;16(1): 94-103.
183. Sydow K, Munzel T. ADMA and oxidative stress. Atheroscler. Suppl. 2003 Dec;4(4): 41-51.
184. Lin KY, Ito A, Asagami T, Tsao PS, Adimoolam S, Kimoto M, et al. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation 2002 Aug;106(8): 987-92.
185. Loomis ED, Sullivan JC, Osmond DA, Pollock DM, Pollock JS. Endothelin mediates superoxide production and vasoconstriction through activation of NADPH oxidase and uncoupled nitric-oxide synthase in the rat aorta. J. Pharmacol. Exp. Ther. 2005 Dec;315(3): 1058-64.
186. Pollock DM, Pollock JS. Endothelin and oxidative stress in the vascular system. Curr. Vasc. Pharmacol. 2005 Oct;3(4): 365-7.
187. Marrero MB, Banes-Berceli AK, Stern DM, Eaton DC. Role of the JAK/STAT signaling pathway in diabetic nephropathy. Am. J. Physiol. Renal. Physiol. 2006 Apr;290(4): F762-8.
188. Hocher B, Schwarz A, Reinbacher D, Jacobi J, Lun A, Priem F, et al. Effects of endothelin receptor antagonists on the progression of diabetic nephropathy. Nephron 2001 Feb;87(2): 161-9.
189. Satoh M, Fujimoto S, Arakawa S, Yada T, Namikoshi T, Haruna Y, et al. Angiotensin II type 1 receptor blocker ameliorates uncoupled endothelial nitric oxide synthase in rats with experimental diabetic nephropathy. Nephrol. Dial. Transplant. 2008 Dec;23(12): 3806-13.
190. Sidharta PN, Wagner FD, Bohnemeier H, Jungnik A, Halabi A, Krahenbuhl S, et al. Pharmacodynamics and pharmacokinetics of the urotensin II receptor antagonist palosuran in macroalbuminuric, diabetic patients. Clin. Pharmacol. Ther 2006 Sep;80(3): 246-56.
191. Arita R, Hata Y, Nakao S, Kita T, Miura M, Kawahara S, et al. Rho kinase inhibition by fasudil ameliorates diabetes-induced microvascular damage. Diabetes 2009 Jan;58(1): 215-26.
192. Lage R, Dieguez C, Vidal-Puig A, Lopez M. AMPK: a metabolic gauge regulating whole-body energy homeostasis. Trends Mol. Med. 2008 Dec;14(12): 539-49.
193. Zhang BB, Zhou G, Li C. AMPK: an emerging drug target for diabetes and the metabolic syndrome. Cell Metab. 2009 May;9(5): 407-16.
194. Zou MH, Wu Y. AMP-activated protein kinase activation as a strategy for protecting vascular endothelial function. Clin. Exp. Pharmacol. Physiol. 2008 May;35(5-6):535-45.
195. Chen ZP, Mitchelhill KI, Michell BJ, Stapleton D, Rodriguez-Crespo I, Witters LA, et al. AMP-activated protein kinase phosphorylation of endothelial NO synthase. FEBS Lett 1999 Jan;443(3): 285-9.
196. Chen Z, Peng IC, Sun W, Su MI, Hsu PH, Fu Y, et al. AMP-activated protein kinase functionally phosphorylates endothelial nitric oxide synthase Ser633. Circ. Res. 2009 Feb;104(4): 496-505.
197. Schulz E, Dopheide J, Schuhmacher S, Thomas SR, Chen K, Daiber A, et al. Suppression of the JNK pathway by induction of a metabolic stress response prevents vascular injury and dysfunction. Circulation 2008 Sep;118(13): 1347-57.
198. Zhang J, Xie Z, Dong Y, Wang S, Liu C, Zou MH. Identification of nitric oxide as an endogenous activator of the AMP-activated protein kinase in vascular endothelial cells. J. Biol. Chem. 2008 Oct;283(41): 27452-61.
199. Kukidome D, Nishikawa T, Sonoda K, Imoto K, Fujisawa K, Yano M, et al. Activation of AMP-activated protein kinase reduces hyperglycemia-induced mitochondrial reactive oxygen species production and promotes mitochondrial biogenesis in human umbilical vein endothelial cells. Diabetes 2006 Jan;55(1): 120-7.
200. Touyz RM, Schiffrin EL. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications. Vascul. Pharmacol. 2006 Jul;45(1): 19-28.
201. Okayasu T, Tomizawa A, Suzuki K, Manaka K, Hattori Y. PPARalpha activators upregulate eNOS activity and inhibit cytokine-induced NF-kappaB activation through AMP-activated protein kinase activation. Life Sci. 2008 Apr 9;82(15-16):884-91.
202. de Aguiar LG, Bahia LR, Villela N, Laflor C, Sicuro F, Wiernsperger N, et al. Metformin improves endothelial vascular reactivity in first-degree relatives of type 2 diabetic patients with metabolic syndrome and normal glucose tolerance. Diabetes Care 2006 May;29(5): 1083-9.
203. Lavu S, Boss O, Elliott PJ, Lambert PD. Sirtuins--novel therapeutic targets to treat age-associated diseases. Nat. Rev. Drug. Discov. 2008 Oct;7(10): 841-53.
204. Nisoli E, Tonello C, Cardile A, Cozzi V, Bracale R, Tedesco L, et al. Calorie restriction promotes mitochondrial biogenesis by inducing the expression of eNOS. Science 2005 Oct;310(5746): 314-7.
205. Ungvari Z, Parrado-Fernandez C, Csiszar A, de Cabo R. Mechanisms underlying caloric restriction and lifespan regulation: implications for vascular aging. Circ. Res. 2008 Mar;102(5): 519-28.
206. Mattagajasingh I, Kim CS, Naqvi A, Yamamori T, Hoffman TA, Jung SB, et al. SIRT1 promotes endothelium-dependent vascular relaxation by activating endothelial nitric oxide synthase. Proc. Natl .Acad. Sci .U S A. 2007 Sep;104(37): 14855-60.
207. Ota H, Eto M, Kano MR, Ogawa S, Iijima K, Akishita M, et al. Cilostazol inhibits oxidative stress-induced premature senescence via upregulation of Sirt1 in human endothelial cells. Arterioscler. Thromb. Vasc. Biol. 2008 Sep;28(9): 1634-9.
208. Potente M, Dimmeler S. NO targets SIRT1: a novel signaling network in endothelial senescence. Arterioscler. Thromb. Vasc. Biol. 2008 Sep;28(9): 1577-9.
209. Potente M, Dimmeler S. Emerging roles of SIRT1 in vascular endothelial homeostasis. Cell Cycle 2008 Jul;7(14): 2117-22.
210. Orimo M, Minamino T, Miyauchi H, Tateno K, Okada S, Moriya J, et al. Protective Role of SIRT1 in Diabetic Vascular Dysfunction. Arterioscler. Thromb. Vasc .Biol. 2009 Jun;29(6): 889-94.
211. Hugo C, Daniel C.Thrombospondin in renal disease. Nephron. Exp. Nephrol. 2009;111(3): e61-6.
212. Hohenstein B, Daniel C, Hausknecht B, Boehmer K, Riess R, Amann KU, et al. Correlation of enhanced thrombospondin-1 expression, TGF-beta signalling and proteinuria in human type-2 diabetic nephropathy. Nephrol. Dial. Transplant. 2008 Dec;23(12): 3880-7.
213. Moczulski DK, Fojcik H, Wielgorecki A, Trautsolt W, Gawlik B, Kosiorz-Gorczynska S, et al. Expression pattern of genes in peripheral blood mononuclear cells in diabetic nephropathy. Diabet Med. 2007 Mar;24(3): 266-71.
214. Isenberg JS, Frazier WA, Roberts DD. Thrombospondin-1: a physiological regulator of nitric oxide signaling. Cell Mol. Life Sci. 2008 Mar;65(5): 728-42.
215. Isenberg JS, Roberts DD, Frazier WA. CD47: a new target in cardiovascular therapy. Arterioscler Thromb. Vasc. Biol. 2008 Apr;28(4): 615-21.
216. Isenberg JS, Martin-Manso G, Maxhimer JB, Roberts DD. Regulation of nitric oxide signalling by thrombospondin 1: implications for anti-angiogenic therapies. Nat. Rev. Cancer 2009 Mar;9(3): 182-94.
217. Isenberg JS, Ridnour LA, Perruccio EM, Espey MG, Wink DA, Roberts DD. Thrombospondin-1 inhibits endothelial cell responses to nitric oxide in a cGMP-dependent manner. Proc. Natl. Acad. Sci. U S A. 2005 Sep;102(37): 13141-6.
218. Isenberg JS, Ridnour LA, Dimitry J, Frazier WA, Wink DA, Roberts DD. CD47 is necessary for inhibition of nitric oxide-stimulated vascular cell responses by thrombospondin-1. J. Biol. Chem. 2006 Sep;281(36): 26069-80.
219. Isenberg JS, Jia Y, Fukuyama J, Switzer CH, Wink DA, Roberts DD. Thrombospondin-1 inhibits nitric oxide signaling via CD36 by inhibiting myristic acid uptake. J. Biol. Chem. 2007 May;282(21): 15404-15.
220. Isenberg JS, Frazier WA, Krishna MC, Wink DA, Roberts DD. Enhancing cardiovascular dynamics by inhibition of thrombospondin-1/CD47 signaling. Curr. Drug. Targets 2008 Oct;9(10): 833-41.
221. Goligorsky MS, Li H, Brodsky S, Chen J. Relationships between caveolae and eNOS: everything in proximity and the proximity of everything. Am. J. Physiol. Renal. Physiol. 2002 Jul;283(1): F1-10.
222. Frank PG, Woodman SE, Park DS, Lisanti MP. Caveolin, caveolae, and endothelial cell function. Arterioscler Thromb. Vasc. Biol. 2003 Jul;23(7): 1161-8.
223. Li XA, Everson WV, Smart EJ. Caveolae, lipid rafts, and vascular disease. Trends Cardiovasc. Med. 2005 Apr;15(3): 92-6.
224. Xu Y, Buikema H, van Gilst WH, Henning RH. Caveolae and endothelial dysfunction: filling the caves in cardiovascular disease. Eur. J. Pharmacol. 2008 May 13;585(2-3):256-60.
225. Pascariu M, Bendayan M, Ghitescu L. Correlated endothelial caveolin overexpression and increased transcytosis in experimental diabetes. J. Histochem. Cytochem. 2004 Jan;52(1): 65-76.
226. Bucci M, Roviezzo F, Brancaleone V, Lin MI, Di Lorenzo A, Cicala C, et al. Diabetic mouse angiopathy is linked to progressive sympathetic receptor deletion coupled to an enhanced caveolin-1 expression. Arterioscler. Thromb. Vasc. Biol. 2004 Apr;24(4): 721-6.
227. Lam TY, Seto SW, Lau YM, Au LS, Kwan YW, Ngai SM, et al. Impairment of the vascular relaxation and differential expression of caveolin-1 of the aorta of diabetic +db/+db mice. Eur. J. Pharmacol. 2006 Sep 28;546(1-3):134-41.
228. Komers R, Schutzer WE, Reed JF, Lindsley JN, Oyama TT, Buck DC, et al. Altered endothelial nitric oxide synthase targeting and conformation and caveolin-1 expression in the diabetic kidney. Diabetes 2006 Jun;55(6): 1651-9.
229. Trujillo J, Ramirez V, Perez J, Torre-Villalvazo I, Torres N, Tovar AR, et al. Renal protection by a soy diet in obese Zucker rats is associated with restoration of nitric oxide generation. Am. J. Physiol. Renal Physiol. 2005 Jan;288(1): F108-16.
230. Garcia-Cardena G, Fan R, Shah V, Sorrentino R, Cirino G, Papapetropoulos A, et al. Dynamic activation of endothelial nitric oxide synthase by Hsp90. Nature 1998 Apr;392(6678): 821-4.
231. Ou J, Fontana JT, Ou Z, Jones DW, Ackerman AW, Oldham KT, et al. Heat shock protein 90 and tyrosine kinase regulate eNOS NO generation but not NO* bioactivity. Am. J. Physiol. Heart Circ. Physiol. 2004 Feb;286(2): H561-9.
232. Lei H, Venkatakrishnan A, Yu S, Kazlauskas A. Protein kinase A-dependent translocation of Hsp90 alpha impairs endothelial nitric-oxide synthase activity in high glucose and diabetes. J. Biol. Chem. 2007 Mar;282(13): 9364-71.
233. Barutta F, Pinach S, Giunti S, Vittone F, Forbes JM, Chiarle R, et al. Heat shock protein expression in diabetic nephropathy. Am. J. Physiol. Renal. Physiol. 2008 Dec;295(6): F1817-24.
234. Potenza MA, Gagliardi S, Nacci C, Carratu MR, Montagnani M. Endothelial dysfunction in diabetes: from mechanisms to therapeutic targets. Curr. Med. Chem. 2009;16(1): 94-112.